electroCore Aims Noninvasive Neurostimulation At The Masses

Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Europe

More from Geography